Clinical Trial Update: A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial of poziotinib in previously treated locally advanced or metastatic non-small cell lung cancer with HER2 exon 20 mutations is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: NSCLC | Phase 3 | Status: SUSPENDED